G1 Therapeutics
g1therapeutics.com
Actively hiring
Health Care
Web Design
Oncology Therapeutics
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$50M
1 round on record
Latest round
$50M
Venture round · Apr 2016 · 10 yr ago
Team
51-200
employees, estimated range
Backers
1
Lumira Ventures
The money's age
Long since its last round
125 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 27, 2016
Raised a round Venture round $50M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2016 | $50M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | G1 Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Gregory MossinghoffExecutive OfficerSEC Form D
Mark VellecaExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Lumira Ventures Similar startupsby what they do, their industry and backers
CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
Yemaachi is creating the world's most diverse cancer bio-database to develop the next generation of cancer drugs that are effective in…
Creating neoantigens by design… …to transform cancer treatments into cures. ATP IS DEVELOPING THE NEXT GENERATION OF TRANSFORMATIVE LIFE…
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
Targeting the Tumor Ecosystem to address cancer drug resistance and improve patients’ lives.
We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
Overview
G1 Therapeutics, Inc. is a commercial stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer.
News
Report
People
Gregory Mossinghoff
Executive Officer
Mark Velleca
Executive Officer, Director
Glenn Muir
Director
Peter Kolchinsky
Director
Christy Shaffer
Director
Ron Laufer
Director
Timothy Sullivan
Director
Seth Rudnick
Director
Frederic Eshelman
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Financials
Total raised
$50M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2016 | $50M | Details |